Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 341

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 341
---
2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company’s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.

    F-11

A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:

 SCHEDULE
OF STOCK OPTION ACTIVITY 

    Weighted average  

    Number of  options  
    Exercise  price  
    Remaining  contractual  life  (in years)  
    Intrinsic value 
  
    Outstanding as of January 1, 2024 
     2,050,197  
    $10.90  
     7.9  
    $36,363 
  
    Granted 
     838,250  
    $1.54  
     -  
    $- 
  
    Forfeited and cancelled 
     (625) 
    $-  
     -  
    $- 
  
    Outstanding as of December 31, 2024 
     2,887,822  
    $8.06  
     7.6  
    $- 
  
    Exercisable as of December 31, 2024 
     1,854,764  
    $11.54  
     6.8  
    $- 
  
    Vested and expected to vest as of December 31, 2024 
     2,887,822  
    $8.06  
     7.6  
    $- 

The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:

 SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES 

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Research and development 
    $624,480  
    $792,273 
  
    General and administrative 
     1,681,369